


Lenalidomide combined with intensive chemotherapy increases the complete remission rate in patients with acute myeloid leukemia and higher risk myelodysplastic syndrome with 5q deletion



82 patients with 5q deletion & AML or higher risk MDS


62/79 (78%) had complex karyotype & 3 unknown karyotypes

Cohort 1 First dose




18/31 responses
58%

Cohort 2 Second dose



19/32 responses
59%

Cohort 3 Third dose



11/19 responses
58%



38/82 (46%) patients achieved complete remission
(58.5% overall response rate)

27/62 (44%) patients with complex karyotype achieved complete remission

21/62 (34%) patients with complex karyotype achieved cytogenetic responses

One-year cumulative incidence of relapse was 64.6%

Median overall survival was 8.2 months